Brokers Issue Forecasts for 10x Genomics Q3 Earnings

10x Genomics, Inc. (NASDAQ:TXG) – Equities researchers at William Blair issued their Q3 2025 earnings estimates for 10x Genomics in a report issued on Thursday, February 13th. William Blair analyst M. Larew forecasts that the company will post earnings per share of ($0.33) for the quarter. The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. William Blair also issued estimates for 10x Genomics’ Q4 2025 earnings at ($0.32) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.02) EPS and FY2026 earnings at ($1.02) EPS.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research report on Saturday, February 1st. Canaccord Genuity Group decreased their price target on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. UBS Group decreased their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Stifel Nicolaus decreased their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Barclays decreased their price target on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating on the stock in a research report on Monday, February 10th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.57.

10x Genomics Price Performance

NASDAQ TXG opened at $12.07 on Monday. 10x Genomics has a 12 month low of $10.80 and a 12 month high of $48.42. The firm has a market capitalization of $1.46 billion, a PE ratio of -7.89 and a beta of 1.85. The company’s 50 day simple moving average is $14.52 and its 200 day simple moving average is $17.22.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its stake in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after buying an additional 1,452 shares during the period. Capital Performance Advisors LLP purchased a new stake in shares of 10x Genomics during the third quarter worth $35,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 136.5% during the third quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after acquiring an additional 1,025 shares in the last quarter. Sound Income Strategies LLC boosted its position in 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in 10x Genomics in the fourth quarter valued at about $52,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.